YG1699
- Generic Name
- YG1699
PK and PD of YG1699 in CKD Patients With Diabetes
Phase 1
Not yet recruiting
- Conditions
- DiabetesRenal Insufficiency, ChronicHemodialysis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06648876
- Locations
- 🇨🇳
Department of nephrology , Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699（Antidiabetic） in Healthy Chinese Sbjects
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Youngene Therapeutics Inc., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05089617
- Locations
- 🇨🇳
Shanghai Xinhua Hospital, Shanghai, Shanghai, China
A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes
Phase 2
Completed
- Conditions
- DiabetesType1diabetesDiabetes MellitusDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Youngene Therapeutics Inc., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT04956263
- Locations
- 🇺🇸
ProSciento, Inc, Chula Vista, California, United States
A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Youngene Therapeutics Inc., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT03953092
- Locations
- 🇺🇸
Frontage Labs, Secaucus, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath